| Communication orales LYSA | EHA 2020 |
|---|---|
| C Herbaux | Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA |
| S Le Gouill | Ibrutinib, Venetoclax plus Obinutuzumab in newly diagnosed Mantle Cell Lymphoma Patients |
